Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Analysis demonstrates additional benefits of adjuvant therapy with clodronate
December 28th, 2004
A new analysis of data from a large-scale study presented at the 27th Annual San Antonio Breast Cancer Symposium demonstrated significant additional benefits with the use of the bisphosphonate clodronate for patients with primary breast cancer, when used in conjunction with standard adjuvant chemotherapy and endocrine therapy. While a previous analysis of the study data showed that adjuvant treatment with clodronate reduced the occurrence of bone metastases and increased survival in this patient group, this new retrospective analysis showed that clodronate treatment also reduced the incidence of skeletal related events (SREs), morbidity, and mortality in the small group...
Source: Cancer Weekly (2004-12-28)
|
